Technical Articles
Mutant oncogene
Application of KRAS G13D & VCB Binding Kit in Targeted Therapy
The KRAS gene is one of the most frequently mutated oncogenes in human cancers, appearing at high frequencies in pancreatic, colorectal, and lung cancers. As a central regulator of cellular signaling pathways, the KRAS protein functions like a molecular switch to control cell division and quiescence.
View details
- Cancer
- KRAS gene
- KRAS G13D
- Mutant oncogene
Application of KRAS G12V & VCB Binding Kit in Targeted Therapy
The KRAS gene is one of the most frequently mutated oncogenes in human malignancies, with this mutation detected in approximately one in seven cancers.
View details
- Cancer
- KRAS gene
- KRAS G12V
- Mutant oncogene
Application of Human KRAS G13D & VCB Binding Kit in KRAS-Targeted Therapy Research
The KRAS gene is one of the most frequently mutated oncogenes in human cancers, occurring in approximately 10-25% of non-small cell lung cancer cases and is closely associated with poor prognosis.
View details
- Cancer
- KRAS G13D
- Mutant oncogene
- Non-small cell lung cancer
Application of Human KRAS G12D & SOS1 Binding Assay Kit in Broad-Spectrum KRAS-Targeted Therapy Research
The KRAS gene, as one of the most frequently mutated oncogenes in human cancers, has long been considered an "undruggable" target due to its protein structural characteristics.
View details
- Drug Research
- KRAS G12D & SOS1 Binding Kit (GDP load)
- Mutant oncogene
- Non-small cell lung cancer
Research Progress on Resistance Mechanisms and Counterstrategies of KRAS G12C Inhibitors
The KRAS gene is one of the most frequently mutated oncogenes in cancer. Due to its protein structure lacking ideal drug-binding pockets and its extremely high affinity for GTP, KRAS mutations have long been considered an "undruggable" target.
View details
- Cancer
- KRAS G12C & CRBN Binding Kit (GDP loaded)
- Mutant oncogene
- Protein structure
- 1
















